Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013

Int J Cardiol. 2014 Jan 1;170(3):e59-62. doi: 10.1016/j.ijcard.2013.11.003. Epub 2013 Nov 13.
No abstract available

Keywords: Acute coronary syndrome; Clinical trial; Clopidogrel; Myocardial infarction; Platelet inhibition; Ticagrelor.

Publication types

  • Letter
  • Comment

MeSH terms

  • Acute Coronary Syndrome / drug therapy*
  • Adenosine / analogs & derivatives*
  • Endpoint Determination / standards*
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use*
  • United States Food and Drug Administration / standards*

Substances

  • Platelet Aggregation Inhibitors
  • Adenosine